



2022 ANNUAL REPORT

Message from
Director

Who are we

Our Institutional
Partners

HCC Registry

Research

Publication

Education &
Training
Nursing Webinars

Training of
Data Entry
Operators

2nd Annual Meet

Financial Report

Connect with us

<https://hemecancer.org/>

MESSAGE FROM DIRECTOR

Hematological cancers are one of the most curable cancers if diagnosed early and treated appropriately. The delivery of treatment in our country has several limitations which include but are not limited to resource constraints, and lack of expertise and knowledge to deliver therapy.



While India has highly skilled professionals in the medical and basic science institutes and numerous institutions that are on par with international peers, these are often limited to major cities and are inaccessible to the poor. The overall number of trained educated health workers is very low in proportion to the country's population. It is widely recognized that there is significant under diagnosis of hematological cancers in India and of those diagnosed, a substantial proportion of patients do not receive standard-of-care therapy. Many of the issues have never been systematically evaluated due to the lack of large well-annotated registry data. Also, treatment strategies and algorithms are often based on studies and data generated in high-income countries, usually in a clinical trial setting, with a different healthcare delivery system that may not necessarily apply in India.

Hematology Cancer Consortium is a multi-center collaborative academic organization established with the aim to improve knowledge, standardized treatment protocols, and cost-effective approaches to management based on locally generated data.

MESSAGE FROM DIRECTOR

We are happy to share that we began our work with 12 leading cancer centers and currently have 26 partners contributing data to the registry and actively participating in research. We are conducting retrospective and prospective studies and working on finding solutions for patients in our country. We are conducting educational and training sessions for - doctors, nurses etc. We are committed to the cause and are now working Indianized treatment protocol. Through this effort we are hopeful we will improve treatment outcome and reduce treatment cost. 6 of our abstracts are accepted at 64th ASH Annual Meeting, 2022.

We are grateful to the donors and our institutional partners for their support.

DR. VIKRAM MATHEWS

DIRECTOR,

HEMATOLOGY CANCER CONSORTIUM

WHO ARE WE

Hematology Cancer Consortium (HCC) is a multi center collaborative organization established to fulfil the long felt need of good quality, cooperative group data in hematological malignancies in India.

OUR GOALS



- Aggregate clinical data to support care outcomes of hematological malignancies
- Develop evidence based, locally relevant treatment protocols and guidelines
- Run investigator initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost effective treatment strategies
- Continuous education to improve awareness and enhance knowledge of therapeutic options for standardization of care in hematological cancers



OUR INSTITUTIONAL PARTNERS

We began with 12 leading Cancer Centers as our institutional partner and we currently have 26 partners.



Rajiv Gandhi Cancer Institute and Research Centre



Believers Church MEDICAL COLLEGE HOSPITAL



Dr. D.K. GOSAVI MEMORIAL
SHRI SIDDHIVINAYAK GANAPATI
CANCER HOSPITAL



HCC REGISTRY

One of the goals of Hematology Cancer Consortium is to aggregate clinical data to support care outcomes of hematological malignancies.

HCC Registries:

Registry	Total Records
Acute Myeloid Leukemia	5345
Acute Lymphocytic Leukemia	4253
Chronic Myeloid Leukemia	2288
Acute Promyelocytic Leukemia	603
Lymphoma	6065


We are focusing on understanding existing challenges and developing appropriate solutions.

Sharing in brief the center wise distribution of records to each of the registry in the year 2022 along with the progress in term of year wise data contribution from various centers across the country since 2018.



HCC REGISTRY

Acute Myeloid Leukemia (AML) Registry

In the year 2022, twenty four centers across the country recorded 1295 Acute Myeloid Leukemia patients' information. The center wise distribution has been summarized in the graph.




Progress





HCC REGISTRY

Acute Lymphocytic Leukemia (ALL) Registry

Twenty two centers across the country recorded 1131 Acute Lymphocytic Leukemia patients' information.




Progress





HCC REGISTRY

Chronic Myeloid Leukemia (CML) Registry

Twenty two centers across the country recorded 958 Chronic Myeloid Leukemia patients' information.




Progress





HCC REGISTRY

Acute Promyelocytic Leukemia (APML) Registry

Twenty centers across the country recorded 172 Acute Promyelocytic Leukemia patients' information.




Progress





HCC REGISTRY

Lymphoma (LYM) Registry

Twenty one centers across the country recorded 2693 Lymphoma patients' information.



Progress



RESEARCH

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

We have validated the machine learning approach of predicting induction mortality with variables relevant to regional clinical settings including baseline infection. The SVM model predicted the risk of both induction mortality as well as morbidity with high accuracy. An online calculator is being developed to help clinicians use this score in regular practice for guiding treatment intensity as per an individual patient's risk and in directing appropriate resource utilization.

(Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study, 64th ASH Annual Meeting, 2022).

Study Title: Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic-phase chronic myeloid leukemia – A multi-center phase II single-arm study (GLaD Study)

The study was conducted between October 2020 till September 2021. Patients were enrolled from 9 centers across India. The interim analysis Dasatinib 50 mg appears to be promising with respect to responses but with a caution considering the fact that the majority of patients had a higher disease load

(Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial, 64th ASH Annual Meeting, 2022)

RESEARCH

Study Title: COVID-19 Hematological Cancers Registry of India (CHCRI Study)

Data collection was retrospective from 21st March 2020 till 30th October 2020 and prospective from 1st November 2020 till 20th March 2021. The status of all patients was updated on May 1st, 2021.

The study is published by:

Blood Cancer Journal - <https://doi.org/10.1038/s41408-021-00599-w>

Study Title: Outcomes and prognostic factors in patients with Burkitt's Lymphoma: Real World Data (BL Study)

A total of 312 patients were included in this study. Out of these 257 patients received treatment and were analyzed for the outcome and prognostic factors.

Our finding is that treatment of adolescent and adult Burkitt lymphoma and leukemia with intensive regimens (high-dose methotrexate-based) and dose adjusted EPOCH regimen resulted in similar survival. Dose-adjusted EPOCH-based regimen was preferred in older patients. The use of rituximab in these patients adds to the overall survival benefit.

(Outcomes and prognostic factors in patients with Burkitt's lymphoma: real world data (64th ASH Annual Meeting, 2022).

Study Title: Epidemiology and treatment outcomes of patients older than 55 years of age with Acute Myeloid Leukemia in India. (HCC Elderly AML)

Retrospective data from 17 institutional members was collected and analysed. Our key finding has been the dual challenge of low rates of treatment initiation and significant treatment discontinuation within one year in patients older than 55 years of age. Poor disease biology is also highlighted by low rates of CR irrespective of initial therapy and low probability of survival at one year

(Epidemiology and treatment outcomes of patients older than 55 years of age with Acute Myeloid Leukemia in India (64th ASH Annual Meeting, 2022).

RESEARCH

Study Title: Care of patients with Acute Myeloid Leukemia during COVID in India - HCC LeucoIn Study

Retrospective analysis of data for adult AML collected from 17 member institutions was compared through two time periods: the pre-COVID period (1st January 2018 through 31st March 2020) and the COVID pandemic period (1st April 2020 through 31st August 2021). Survival and follow-up data were analyzed as on 31st May 2022. A total of 2998 patients, were registered (2003 in the pre-COVID period and 995 during the COVID pandemic).

Our data suggest that continuing standard of care in treatment-emergent AML even during the pandemic is feasible and intensive induction chemotherapy and transplant should still be offered for eligible patients

(Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience, 64th ASH Annual Meeting, 2022).

Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality

We analysed the data for patients with newly diagnosed APL from two large tertiary care centers in India, registered between 2013-2018 to evaluate the outcomes in all risk groups (as per Sanz score), mortality within first 30-days and prognostic factors. Patients with low/intermediate risk were treated with ATRA and ATO based therapy whereas the high-risk group received chemotherapy in addition to ATRA/ATO. A total of 238 patients were included in this analysis.

The retrospective analysis highlights that ATO+ATRA and minimal anthracycline based therapy has led to similar outcomes in all risk groups and the present need to address induction mortality. High induction mortality in patients with WBC >40,000/cum indicates the potential contribution of infections due to use of steroids to treat differentiation and underlying coagulopathy or a different biology.

(Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality: 64th ASH Annual Meeting, 2022).

RESEARCH

UPCOMING CLINICAL TRIAL

Study Title: Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study).

- Study design: Phase III open labeled Randomized Control Trial
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Objective: To evaluate the net treatment benefit (event-free survival, documented infections, differentiation syndrome, hepatotoxicity and neuropathy in decreasing order) between the two study arms.
- Indication: Patient newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.
- Update: Protocol writing is complete. Designed ICF's and CRF. Site evaluation criteria is ready. Synopsis along with NDA has been shared with the members.

PUBLICATIONS

Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

British Journal of Haematology

<https://www.hemecancer.org/pdf/bjh.17268.pdf>

DOI: 10.1111/bjh.17268

Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India

Blood 2018; 132 (Supplement 1): 4006.

<https://doi.org/10.1182/blood-2018-99-116853>

Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India

Blood Cancer Journal

<https://doi.org/10.1038/s41408-021-00599-w>

EDUCATION & TRAINING






NURSING WEBINARS

We are pleased to share that the HCC nurses group had initiated an education program to enhance knowledge. First nursing webinar was conducted on 27 April 2021.

Eighteen webinars have been conducted so far. Webinars are held on the last Tuesday of every month. More than 100 nurses participate in these webinars.

Thank you, team!

Nursing Webinars conducted since January-2022:

Topic: Childhood and Young All Sticking to Protocol - A Nursing Perspective Speaker: Capt. Monika, BSC nursing, Diploma in oncology nursing, Hematology day-care and BMT, Command Hospital, Kolkata	
Topic: Childhood and Young All Sticking to Protocol - A Nursing Perspective Speaker: Lt Gunjan Rawat, BSC(Hons) nursing, Hematology day-care and BMT, Command Hospital, Kolkata	
Topic: Role of Nurses in Bone Marrow Transplant Speaker: Sindhu S, BMT In charge, Malabar Cancer Center, Thalassery, Kannur, Kerala	
Topic: PICC insertion care & maintenance Speaker: Jyothi Vidya, Senior Registered Nurse, HCGMSR Cancer hospital, Bangalore	
Topic: Common investigations in Hemato-Oncology (BMT) Speaker: Preethi S, Nursing Officer, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry	

EDUCATION & TRAINING

NURSING WEBINARS

<p>Topic: Extravasation it's Prevention and Management</p> <p>Speaker: Ms. Surya Sukumaran, Senior Nurse Educator, Rajiv Gandhi Cancer Institute and Research Center, Delhi</p>	
<p>Topic: Palliative Nursing Improving Quality of Life of Oncology Patients</p> <p>Speaker: Ms. Rekha Kuchekar, Palliative Care Nurse, Tata Memorial Hospital, Mumbai</p>	
<p>Topic: Infection Control Practices in Hematology</p> <p>Speaker: Mrs. Amalorpavamari Lucas, Professor & Head, Hemato Oncology Nursing, CMC Vellore</p>	
<p>Topic: Filtration in BMT</p> <p>Speaker: Ms. Mita Roychowdhury, Clinical Nurse Specialist, Bone Marrow Transplant Unit, Tata Medical Center, Kolkata</p>	

Webinar recordings are available on our website:

<http://hemecancer.org/>

Register as a member to access recordings -

<http://hemecancer.org/webinar-recording.php>

TRAINING OF DATA ENTRY OPERATORS

Hematology Cancer Consortium believes in delivering accurate and good-quality data. To encourage this, HCC organizes various training programs for our Data Entry Operators and conducts source data verification as it accrues to ensure the quality of the data generated, provide evidence for the integrity of data at the time of publication and to minimize the missing data.

We conducted a special workshop for DEO's on 27th and 28th May 2022 in collaboration with the CDMC team.

Basics about Hematologic cancers	Dr. Manju Sengar
CDMC: Data collection system & Data quality	Dr. Prasanna Samuel
HCC online platform & Pitfalls in data collections with examples	Mr. Omprakash
Overview & explanation of terminologies used in software: APML ALL AML CML Lymphoma	Dr. Hasmukh Jain Dr. Prasanth Ganesan Dr. Manju Sengar Dr. Rajan Kapoor Dr. Anu Korula

We also conducted a training workshop for DEO's on 21st October 2022 during our Second Annual Meet at TMH, Mumbai

DEO workshop training program recordings are now available on the HCC website:

<https://hemecancer.org/training-module.php>

HCC 2ND ANNUAL MEET

Our Second Annual Meeting was conducted in association with the Society of Hematologic Oncology (SOHO) from October 21st to October 23rd, 2022 at Rustom Choksi Auditorium, Tata Memorial Hospital, Mumbai

The goal was to bring state-of-the-art data along with relevant abstracts to an audience with an interest in hematologic malignancies. Experts shared information on recent advances in the field of hematological malignancies that impacts clinical management with a special focus on regionally relevant research.

Highlights:

- 502 Participants attended the program.
- Received 85 Abstracts and were presented as a poster.
- Training sessions, panel discussions, and skill stations were organized during the nurses' workshop. We focused on Chemotherapy, Good Clinical Practices for HPC Infusion and Blood Transfusion: Nursing Perspective and CVAD Workshop.
- Patient Advocacy group was formed and was hosted during the Annual Meet.

We conducted:

- Data Entry Operators Training Session
-

HCC 2ND ANNUAL MEET

- Nurses Workshop - Closing gaps: Translating guidelines into best nursing practices

- Scientific Program focusing:

Session 1 - Acute Lymphoblastic Leukemia: Recent Advances

Session 2 - Chronic Myeloid Leukemia – Standard of Care in 2022

Session 3 - Is it Time to Re-Define the Standard of Care in AML

Session 4 - How to make Multiple Myeloma Care more Equitable Globally?

Session 5 - Management of Non-Hodgkin lymphoma

Session 6 - Myeloproliferative Neoplasms

- Patient Advocacy Session



The annual meeting session recordings and photos are available on HCC website: <https://hemecancer.org/>

FINANCIAL REPORT

Independent Auditor's Report

M. P. Chitale & Co.

Chartered Accountants

Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001 • Tel.: 2265 1186 / 2265 3023 / 24 • E-mail: office@mpchitale.com

INDEPENDENT AUDITOR'S REPORT

To the Members of
Hematology Cancer Consortium- Association (HCCA)
Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Hematology Cancer Consortium- Association (hereinafter referred to as "HCCA") ("the Company") having its registered office Shop no. 1A, Ground Floor, Deep Co-operative Housing Society Limited, Jerbai Wadia Road, Parel Bhoiwada, Mumbai, 400012, for the year ended March 31, 2023, which include the Balance Sheet as at that date and the Statement of Income and Expenditure for the period from April 01, 2022 to March 31, 2023 and Cash Flows Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and its surplus and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for



FINANCIAL REPORT

Independent Auditor's Report

cont..

M. P. Chitale & Co.
Chartered Accountants

safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls; that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or taken together, they could reasonably be expected to influence the economic decisions of users taken based on these Standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Consider the internal control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.



FINANCIAL REPORT

Independent Auditor's Report

cont..

M. P. Chitale & Co.
Chartered Accountants

- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- iv. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- v. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide management with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company as far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
- d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as April 1, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of Section 164 (2) of the Act.



FINANCIAL REPORT


Independent Auditor's Report

cont..

M. P. Chitale & Co.
Chartered Accountants

- (e) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- The Company does not have any pending litigations, which would impact its financial position
 - The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses
 - There were no amounts, which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - The Management has represented that, to the best of its knowledge and belief, as disclosed in the note to the accounts 2(j), no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
 - The Management has represented, that, to the best of its knowledge and belief, as disclosed in the note to the accounts 2(k), no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

For M. P. Chitale & Co.
Chartered Accountants
ICAI FRN: 101851W


Ashutosh Pednekar
Partner
ICAI M No.: 041037
UDIN: 23041037BGPVOP8224
Place: Mumbai
Date: August 14, 2023




ZAUSER\HCCA\FY 2022-23\Final\Final Audit Report FY 22-23.docx

FINANCIAL REPORT

Balance sheet as at March 31, 2023


Hematology Cancer Consortium- Association			
CIN: U85100MH2020NPL335745			
Balance Sheet as at March 31, 2023		In ₹ (Hundred Of Rupees)	
Particulars	Note No.	As at 31-Mar-2023	As at 31-Mar-2022
EQUITY AND LIABILITIES			
Sources of Funds			
(a) Corpus fund		-	-
(b) Reserves and Surplus	1	49,869.22	44,825.28
Current Liabilities			
(a) Other Current Liabilities	2	18,601.35	3,640.83
(b) Short-term provisions	3	2,408.86	300.00
Total		70,879.43	48,766.11
ASSETS			
Non-Current Assets			
(a) Property, Plant and Equipment	4	3,913.08	1,711.37
(b) Other Non-Current Assets	5	4,855.20	1,222.91
Current Assets			
(a) Cash and Cash Equivalents	6	56,391.25	45,208.94
(b) Short-term loans and advances	7	772.64	-
(c) Other current Asset	8	4,900.00	528.36
(d) Preliminary Expenditure		47.27	94.53
Total		70,879.43	48,766.11
Also see accompanying Notes to and forming part of the Financial Statements	12		

As per our report attached.
For M. P. Chitale & Co.
Chartered Accountants
Firm Regn. No.101851W


Ashutosh Pednekar
Partner
M No.: 041037
Date: August 14, 2023
Place: Mumbai



For and On behalf of the Board
Hematology Cancer Consortium- Association


Niyati Sutaria James
Director
DIN: 09428177
Date: August 14, 2023
Place: Mumbai


Palani Thyagarajan
Director
DIN: 09428178
Date: August 14, 2023
Place: Mumbai




FINANCIAL REPORT

Statement of Income and Expenditure for the period ended March 31, 2023


Hematology Cancer Consortium- Association				
CIN: U85100MH2020NPL335745				
Statement of Income and Expenditure for the year ended March 31, 2023			In ₹ (Hundred Of Rupees)	
SR No	Particulars	Note No.	For the year ended 31-MAR-23	For the year ended ON 31-MAR-22
I	Donations, Grants & Sponsorships	9	1,97,653.35	1,19,781.97
II	Other Income	10	2,619.31	2,366.23
III	TOTAL REVENUE (I + II)		2,00,272.66	1,22,148.20
IV	EXPENSES			
	Expenses on Objects of Section 8 Company	11	1,93,268.98	1,07,389.81
	Depreciation	4	623.00	379.53
	Amortization of preliminary expenses		47.26	47.26
	Administration Expenditure		1,289.48	205.96
	TOTAL EXPENSES		1,95,228.72	1,08,022.56
V	Surplus Before Tax		5,043.94	14,125.64
VI	Tax Expense		-	-
	Current Tax		-	-
	Deferred Tax		-	-
VII	Surplus for the Period(V-VI)		5,043.94	14,125.64
	Also see accompanying Notes to and forming part of the Financial Statements	12		


As per our report attached.
For M. P. Chitale & Co.
Chartered Accountants
Firm Regn. No.101851W


Ashutosh Pednekar
Partner
M No.: 041037
Date: August 14, 2023
Place: Mumbai



For and On behalf of the Board
Hematology Cancer Consortium- Association


Niyati Sutaria James
Director
DIN: 09428177
Date: August 14, 2023
Place: Mumbai



Palani Thyagarajan
Director
DIN: 09428178
Date: August 14, 2023
Place: Mumbai

FINANCIAL REPORT

Cash flow statement



Hematology Cancer Consortium- Association		
CIN: U85100MH2020NPL335745		
Cash Flow Statement for the Year ended March 31, 2023		
Particulars	31-Mar-2023	31-Mar-2022
A. Cash flow from operating activities		
Surplus Before Tax	5,043.94	14,125.64
Adjustments for:		
Amortization Expenses	-47.26	-47.26
Depreciation	670.26	426.79
Operating cash flows before changes in assets/liabilities	5,666.94	14,505.17
Changes in assets/liabilities		
Increase/(decrease) in other current liabilities	14,960.52	-73,991.02
Increase/(decrease) in short-term provisions	2,108.86	300.00
(Increase)/decrease Long-term loans and advances	-	-
(Increase)/decrease in Other Non current Assets	-3,632.29	-900.00
(Increase)/decrease in short-term loans and advances	-5,097.02	230.94
Cash generated from operating activities	14,007.00	-59,854.90
Net cash flows generated from operating activities (A)	14,007.00	-59,854.90
B. Cash flow from investing activities		
Purchase of Property, Plant and Equipment	-2,824.70	-2,090.90
Net cash flow generated from investing activities (B)	-2,824.70	-2,090.90
C. Cash flow from financing activities		
Issue of share capital		
Net cash flow generated from financing activities (C)	-	-
Net increase in cash and cash equivalents (A+B+C)	11,182.30	-61,945.81
Cash and Cash Equivalents as at the beginning of the year	45,208.94	1,07,154.75
Cash and Cash Equivalents as at the end of the year	56,391.25	45,208.94
Also see accompanying Notes to and forming part of the Financial Statements	12	

As per our report attached.
For M. P. Chitale & Co.
Chartered Accountants
Firm Regn. No.101851W


Ashutosh Pednekar
Partner
M No.: 041037
Date: August 14, 2023
Place: Mumbai



For and On behalf of the Board
Hematology Cancer Consortium- Association

 
Niyati Sutaria James Palani Thyagarajan
Director Director
DIN: 09428177 DIN: 09428178
Date: August 14, 2023 Date: August 14, 2023
Place: Mumbai Place: Mumbai



FINANCIAL REPORT

Fixed Assets

Hematology Cancer Consortium- Association

CIN: U85100MH2020NPL335745

Notes Forming part of the Financial Statements

Note 4 -Property, Plant and Equipment

In ₹ (Hundred Of Rupees)

DESCRIPTION	RATE	GROSS BLOCK				DEPRECIATION			NET BLOCK		
		AS ON 01.04.2022	ADDITIONS DURING THE YEAR	SALES/ADJ. DURING THE YEAR	AS ON 31.03.2023	PROVIDED UPTO 31.03.2022	DEDUCTION/ ADJUSTMENT	PROVIDED FOR THE YEAR	TOTAL UPTO 31.03.2023	AS ON 31.03.2023	AS ON 31.03.2022
Furniture	9.50%	-	2,402.70	-	2,402.70	-	-	57 18/25	57.72	2,344.98	-
Computer	31.67%	2,090.90	-	-	2,090.90	379.53	-	541.99	921.52	1,169.38	1,711.37
Equipments	19.00%	-	422.00	-	422.00	-	-	23.29	23.29	398.71	-
TOTAL (A)		2,090.90	2,824.70	-	4,915.60	379.53	-	623.00	1,002.53	3,913.08	1,711.37
PERVIOUS YEAR		-	2,090.90	-	2,090.90	-	-	379.53	379.53	-	1,711.37
TOTAL ASSETS		2,090.90	2,824.70	-	4,915.60	379.53	-	623.00	1,002.53	3,913.08	1,711.37



FINANCIAL REPORT

Schedules / Notes

Hematology Cancer Consortium- Association		
CIN: U85100MH2020NPL335745		
Notes Forming part of the Financial Statements	In ₹ (Hundred Of Rupees)	

Note 1 : Reserves & Surplus

	31-Mar-2023	31-Mar-2022
Opening Balance	44,825.28	30,699.64
Add: Surplus carried over to balance sheet	5,043.94	14,125.64
Total	49,869.22	44,825.28

Note 2 :Current liabilities

	31-Mar-2023	31-Mar-2022
Sundry Creditors	95.80	1,416.00
Grant Payable	4,500.00	-
Grant Payable (Unutilized)	14,005.55	2,224.83
Total	18,601.35	3,640.83

Note 3 : Short-term provisions

	31-Mar-2023	31-Mar-2022
Provision for Expenditure	2,408.86	300.00
Total	2,408.86	300.00

Note 5 :Other Non-Current Assets

	31-Mar-2023	31-Mar-2022
TDS Receivable	3,855.20	1,220.65
Rent Deposit	1,000.00	-
Others	-	2.26
Total	4,855.20	1,222.91

Note 6:Cash & Bank Balances

	31-Mar-2023	31-Mar-2022
Bank Balances in Savings Account with HDFC Bank		
Account No. 50100347097089	35,647.74	37,611.10
Account No. 50100392097440	20,743.51	7,330.56
Fixed Deposits	-	250.00
Interest Accrued on Fixed Deposits	-	17.28
Total	56,391.25	45,208.94



FINANCIAL REPORT

Schedules / Notes

cont..

Note 7: Short-term loans and advances

	31-Mar-2023	31-Mar-2022
Advance to Creditors	772.64	-
Total	772.64	-

Note 8: Other current Asset

	31-Mar-2023	31-Mar-2022
Grants & Sponsorships Receivable	4,900.00	-
Prepaid Expenditure	-	528.36
Total	4,900.00	528.36

Note 9: Donations, Grants & Sponsorships

	31-Mar-2023	31-Mar-2022
Donation	30.00	-
Grant	93,148.67	1,19,781.97
Sponsorship	1,04,474.68	-
Total	1,97,653.35	1,19,781.97

Note 10: Other Income

	31-Mar-2023	31-Mar-2022
Saving Bank Interest	2,607.92	2,348.95
FDR Interest	9.71	17.28
Interest on Income tax refund	1.68	-
Total	2,619.31	2,366.23

Note 11: Expenses on Objects of Section 8 Company

	31-Mar-2023	31-Mar-2022
Research Activity	1,74,183.61	91,638.98
Professional Fees	18,203.01	11,958.19
Insurance	528.36	1,074.68
Audit Fee	354.00	300.00
Other Expenditure	-	2,417.95
Total	1,93,268.98	1,07,389.81



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2023

Hematology Cancer Consortium-Association

CIN No: U85100MH2020NPL335745

NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS AT THE YEAR ENDED MARCH 31st, 2023

Note 12

1. Corporate Information:

Hematology Cancer Consortium-Association (the Company) is a private company limited by guarantee registered under section 8 of the Companies Act, 2013. The Company was incorporated on January 09, 2020. Object of the company is to initiate a web based online data collection platform for hematological cancers, bio-banking of samples from cases with hematological cancers in each of the participating centers, analyzing the respective data and plan prospective collaborative studies in the relevant field, facilitating basic scientific research to understand the biology of the disorders, developing common treatment protocols and specific guidelines for management of hematological cancers, disseminating the knowledge and information to the physicians, patients, volunteers and other sections of the society as may be deemed fit, facilitating access to standard care treatment for patients diagnosed with hematological cancers and to do all the related or supportive or ancillary activities with respect to hematological cancers.

2. Significant Accounting Policies:

a. Basis of Accounting

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) in compliance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and the relevant provisions of the Companies Act, 2013 ("the 2013 Act"). The financial statements have been prepared on accrual basis under the historical cost convention.

The Company is a Small and Medium size Company (SMC) as defined in the general instructions in respect of Accounting Standards notified under the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to small and medium size Company.

b. Use of Estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles require estimates and assumptions to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and differences between actual results and estimates are recognized in the periods in which the results are known/materialized.



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2023

cont..

c. **Revenue Recognition**

Donations received towards Hematology Cancer Consortium-Association are considered as income when received. Grants and Sponsorship are recognized as income based on the irrespective contractual terms. Revenue is recognized when it is earned and no significant uncertainty exists as to its realization or collection.

d. **Corpus Funds**

Receipts in the form of voluntary contribution made with a specific direction to be treated as corpus are recognized as Corpus Funds.

e. **Related party transactions**

In ₹ (Hundred Of Rupees)			
Description of Relationship	Names of related parties	1-April-2022 to 31-Mar-2023	8-December-2021 to 31-Mar-2022
Key Management Personnel (KMP)	Remuneration to Bhavisha Sanadhya – CEO	12,900.00	2,700.00

f. **Income Tax**

Current tax, if any is the amount of tax payable on the taxable income for the year as determined in accordance with the applicable tax rates and provision of the Income Tax Act, 1961. The Company is registered under section 8 of the Companies Act, 2013. The Company is exempt from the payment of Income tax. No provision for taxation has been made in the accounts in view of the exemption eligible to the Company under Section 11 read with Section 2(15) of the Income tax Act 1961

g. **Provisions, Contingent Liabilities & Contingent Assets**

A provision is recognized when the company has a present legal obligation as a result of past events and it is probable that an out flow of resources will be required to settle the obligation is respect of which a reliable estimate can be made. Provisions (excluding employee benefits) are not discounted to present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

h. **Depreciation**

Depreciation on property, plant and equipment is provided on the straight-line method at the rates reflective of the estimated useful life of the assets estimated by the management.



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2023

cont..

i. **Utilisation of Borrowed funds and share premium**

- The Company has not granted any advance/loans or investments or provided guarantee or security or the like to any other person(s) or entities with an understanding, whether recorded in writing or otherwise, to further lend/invest/provide guarantee or security or the like to any other person on behalf of the company.
- The Company has not received any funds from any person(s) or entities with an understanding, whether recorded in writing or otherwise, that the company shall further lend or invest or provide guarantee or security or the like in any other person on behalf of and identified by such person(s)/entities.

j. Previous year figures have been regrouped/reclassified wherever necessary, in order to make them comparable.

3. **Details on Benami Property Held**

No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transaction (Prohibition) Act, 1988 (45 of 1988).

4. **Borrowing from Banks and Financial Institutions on Security of Current Assets**

The Company does not have any borrowing facilities taken from Banks or Financial Institution.

5. **Willful Defaulter**

The Company has not been declared as a willful defaulter by any bank (as defined under the Companies Act, 2013), in accordance with the guidelines on willful defaulter issued by the Reserve Bank of India.

6. **Relationship with Struck Off Companies**

The Company does not have any transaction with Companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.

7. **Registration of charges or satisfaction with the Registrar of Companies**

There are no changes or satisfaction yet/pending to be registered with the Registrar of Companies at the end of the year.

8. **Compliance with number of layer Companies**

The company does not have any subsidiary accordingly compliance with the number of layers prescribed under caluse87 of section 2 of the companies act read with Companies (Restriction on number of Layers) Rule 2017 is not applicable.



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2023

cont..

9. Financial Ratio

Sr. No.	Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason for Variance
1	Current Ratio	Current Assets	Current Liabilities	NA	NA		
2	Debt Equity Ratio	Total Debts	Shareholder's Equity	NA	NA		
3	Debt Service Coverage Ratio	Earning available for debt service	Debt Service	NA	NA		
4	Return on Equity (ROE)	Net Profit after taxes- preference Dividend	Average Shareholder's Equity	NA	NA		
5	Inventory Turnover Ratio	Cost of Goods sold or Sales	Average Inventory	NA	NA		
6	Trade Receivables Turnover Ratio	Net Credit Sales	Average Account Receivable	NA	NA		
7	Trade Payables Turnover Ratio	Net Credit Purchase/ Expenses	Average Trade Payable	NA	NA		
8	Net Capital Turnover Ratio	Net Sales	Working Capital	NA	NA		
9	Net Profit Ratio	Net Profit	Net Sales	NA	NA		
10	Return on Capital employed (ROCE)	Earning before Interest and Taxes	Capital Employed	NA	NA		

- Current Ratio = Current Assets / Current Liability
- Debt-equity ratio = Total Debt/ Shareholder's Equity
- Debt service coverage ratio = Earnings available for debt service / Debt Service
- Return on equity ratio = Net Profits after taxes – Preference Dividend (if any) / Average Shareholder's Equity
- Inventory turnover ratio = Cost of goods sold OR sales/ Average Inventory
- Trade receivables turnover ratio = Net Credit Sales/ Average Accounts Receivable
- Average trade debtors = (Opening + Closing)/2
- Trade payables turnover ratio = Net Credit Purchases/ Average Trade Payable
- Net capital turnover ratio = Net Sales/ Average Working Capital
- Net profit ratio= Net Profit / Net Sales



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2023

cont..

- Return on capital employed= Earning before interest and taxes / Capital Employed
Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability
- Return on investment= $\frac{MV(T1) - MV(T0) - \text{Sum } [C(t)]}{\{MV(T0) + \text{Sum } [W(t) * C(t)]\}}$

T1 = End of time period

T0 = Beginning of time period

t = Specific date falling between T1 and T0






MV(T1) = Market Value at T1

MV(T0) = Market Value at T0

C(t) = Cash inflow, cash outflow on specific date

W(t) = Weight of the net cash flow (i.e. either net inflow or net outflow) on day 't', calculated as $[T1 - t] / T1$

Since the company is incorporated under section 8 of the companies act, 2013 and it has no commercial activities and borrowings, the above ratios are not applicable.

For M. P. Chitale & Co. Chartered Accountants FRN: 101851W  Ashutosh Pednekar Partner M.No: 041037 	For and on behalf of the Board of Directors  Niyati Sutaria James Director DIN: 09428177	  Palani Thyagarajan Director DIN: 09428178 
---	---	---

CONNECT WITH US

HCC is deeply grateful to its individual & corporate supporters for their generosity.

You can join us on:



CONTACT US

EMAIL: ADMIN@HEMECANCER.ORG